This report was first published by Endpoints News. To see the original version, click here
A few months of momentum have cemented hope that the worst of biotech’s bear market is in the rearview mirror, galvanizing industry insiders who have clung to cautious optimism for multiple years.
Since bottoming out in early April when President Donald Trump threatened sweeping reciprocal tariffs, the $XBI has risen more than 50%, and is up 13% in the last month. The NYSE index $DRG, an index that includes numerous large pharmaceutical stocks, is up 5% in the last month. That’s far better than the broader S&P 500, which biotech stocks have outperformed over the last half-year.
您已閱讀11%（673字），剩余89%（5691字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。